Immunological response after early extra and regular MMR immunization: 10 years follow-up

Observational study on immunological response 2 years after MMR-2 vaccination in children that received early extra or regular MMR immunization as infants to assess long-term effect of early extra MMR immunization

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN85713294

Enrollment

Registered

2023-10-05

Start date

2023-10-09

Completion date

Unknown

Last updated

2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Measles immunization in children Infections and Infestations

Interventions

In this follow-up study, a single small blood sample will be collected by finger-stick of children who previously were immunized with an MMR-0 vaccination between 6-12 months of age and children of a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Current inclusion criteria as of 30/01/2024: 1. Participation in the study on the immunological effects of early extra measles vaccination, as described in a separate study protocol (NL45616.094.13/IIV-273) or participation in the BMR-nul-study on epidemiological effects of early extra measles vaccination as described in a separate study protocol 2. The parents/legal representatives accept participation in the trial according to the described procedures 3. Presence of an informed consent signed by both parents/legal representatives 4. Children must have received the MMR-2 vaccination Previous inclusion criteria: 1. Participation in the study on the immunological effects of early extra measles vaccination, as described in a separate study protocol (NL45616.094.13/IIV-273) 2. The parents/legal representatives accept participation in the trial according to the described procedures 3. Presence of an informed consent signed by both parents/legal representatives 4. Children must have received the MMR-2 vaccination

Exclusion criteria

Exclusion criteria: 1. Presence of a serious disease that requires medical care that can interfere with the results of the study 2. Known or suspected immunological disorder 3. Bleeding disorders

Design outcomes

Primary

Measure	Time frame
Measles-specific serum IgG measured by Luminex multiplex-based serology and virus-neutralizing antibodies by Plaque Reduction Neutralization Test (PRNT) 2 years (+/- 2 months) after MMR-2 vaccination	—

Secondary

Measure	Time frame
Serum IgG antibody concentrations against mumps and rubella measured by Luminex multiplex-based serology 2 years (+/- 2 months) after MMR-2 vaccination	—

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026